Regentis Biomaterials

RGNT

市值 US$1047萬

Engagement with leading orthopedic surgeons and cartilage repair specialists highlights growing awareness of GelrinC's off-the-shelf regenerative technology GelrinC is CE Mark approved in Europe, where Regentis is expanding its network of Centers of Excellence to support surgeon training and commercialization efforts European clinical sites also support the Company's ongoing U.S. FDA pivotal Phase III trial HERZLIYA, ISRAEL / ACCESS Newswire / October 12, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced strong interest and engagement from orthopedic surgeons, physicians and cartilage repair specialists who visited the Company's booth at the 8th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, held October 8-10, 2026, in Porto, Portugal.

HERZLIYA, IL / ACCESS Newswire / October 9, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that Ehud Geller, Chief Executive Officer and Executive Chairman, will present at the 2026 ThinkEquity Conference on Thursday, October 15, 2026.

AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of  The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness, including surgeon training and regulatory approval of new manufacturing process that improves production yield 400% Strengthened balance sheet with $6.5 million private placement in June 2026 HERZLIYA, IL / ACCESS Newswire / September 11, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today reported financial results for the six months ended June 30, 2026 and provided a corporate and clinical update.

Patent expands intellectual property protection in one of the world's largest cartilage repair markets GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell harvesting, lab processing, and surgeries-potentially setting a new standard of care for knee cartilage repair HERZLIYA, IL / ACCESS Newswire / July 20, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today that the Japan Patent Office has issued a Notice of Allowance for the Company's patent application titled "Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof" for its proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC®, the Company's regenerative treatment for articular cartilage injuries.

European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production GelrinC®, which is approved for sale in the European Union, is pioneering knee cartilage repair with an off-the-shelf cell-free hydrogel implant HERZLIYA, IL / ACCESS Newswire / July 15, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today it has received approval from the European Notified Body to manufacture GelrinC® using its next-generation solvent-free manufacturing process.

HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that it has entered into definitive securities purchase agreements with accredited and institutional investors for the issuance and sale of ordinary shares (or pre-funded warrants in lieu thereof) together with warrants , at a purchase price of $3.50 per ordinary share and accompanying ordinary warrant (or $3.4999 per pre-funded warrant and accompanying ordinary warrant), in a private placement, for expected aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and estimated offering expenses payable by us.

GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European Union Regentis is growing its network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC GelrinC's 10-minute procedure offers a safe and effective alternative to traditional microfracture and complex cell-based therapies addressing a $3 billion U.S. market HERZLIYA, ISRAEL / ACCESS Newswire / June 8, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC® in Europe, where it has CE Mark approval.

Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption Renowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence network Strengthens surgeon engagement and expands Regentis' European commercialization infrastructure HERZLIYA, IL / ACCESS Newswire / April 16, 2026 / Regentis Biomaterials Ltd.

Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year Proprietary process is already patented in several countries and is pending in the U.S. HERZLIYA, IL / ACCESS Newswire / March 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced it has developed a new manufacturing process for its lead product, GelrinC®, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage.